Halozyme Therapeutics, Inc. (HALO) Stock Score, Valuation & Financial Research
Halozyme Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 40/100.
Quick answer for HALO
Halozyme Therapeutics, Inc. currently has a Wall Street Score of 40/100. The stored market price is $108.44. Its financial score is 19/100. Its valuation score is 4/100. The latest WSS change is -6.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Halozyme Therapeutics, Inc. does
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during sub
HALO financial snapshot
- Wall Street Score:
- 40/100
- Current price:
- $108.44
- Market capitalization:
- $12.86B
- Revenue:
- $1.66B
- Net income:
- $413.6M
- Free cash flow:
- $644.6M
- Cash:
- $163.1M
- Total debt:
- $2.15B
- EPS:
- 2.64
- P/E ratio:
- 41.1x
- Financial score:
- 19/100
- Valuation score:
- 4/100
- Revenue score:
- 51/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $644.6M, showing positive cash generation.
- The balance sheet shows $163.1M of cash versus $2.15B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -6.4 points: HALO decreased 6.4 points because Capital declined by 6 points, Valuation declined by 29.3 points.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HALO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.